A Phase I Study of Eribulin, a Novel Microtubule Inhibitor, in Children With Refractory or Recurrent Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 01 Mar 2019
Price : $35 *
At a glance
- Drugs Eribulin (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions
- Acronyms ERIBULIN
- 22 Feb 2019 Status changed from recruiting to completed.
- 29 Mar 2017 Planned End Date changed from 1 Dec 2015 to 1 Jun 2018.
- 29 Mar 2017 Planned primary completion date changed from 1 Dec 2015 to 1 Jun 2018.